We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Tools
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| C4x Discovery Holdings Plc | LSE:C4XD | London | Ordinary Share | GB00BQQ2RV18 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -0.725 | -5.58% | 12.275 | 195,201 | 16:35:28 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 11.80 | 12.75 | ||||
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 2.7M | -8.16M | -0.0324 | -4.01 | 32.79M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 17:06:02 | O | 15,000 | 12.275 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 05/10/2023 | 13:35 | UKREG | C4X Discovery Holdings PLC Holding(s) in Company |
| 02/10/2023 | 11:36 | UKREG | C4X Discovery Holdings PLC Block listing Interim Review |
| 29/9/2023 | 10:14 | UKREG | C4X Discovery Holdings PLC Grant of Options and Directors Dealing |
| 28/9/2023 | 14:52 | UKREG | C4X Discovery Holdings PLC Holding(s) in Company |
| 01/9/2023 | 06:00 | UKREG | C4X Discovery Holdings PLC Total Voting Rights |
| 18/8/2023 | 11:45 | UKREG | C4X Discovery Holdings PLC Exercise of Options, Issue of Equity and TVR |
| 17/8/2023 | 14:36 | ALNC |  TAKING AIM: Shore impressed by C4X Discovery's promising portfolio |
| 01/8/2023 | 16:39 | ALNC | TRADING UPDATES: C4X Discovery inks Indivior deal, Digitalbox expands |
| 01/8/2023 | 06:00 | UKREG | C4X Discovery Holdings PLC Divestment of Orexin-1 to Indivior for GBP15.95m |
| 20/6/2023 | 09:52 | ALNC | C4X Discovery chair steps down; Clive Dix named interim chair & CEO |
C4x Discovery (C4XD) Share Charts1 Year C4x Discovery Chart |
|
1 Month C4x Discovery Chart |
Intraday C4x Discovery Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 15/11/2023 | 15:10 | C4X Discovery Holdings plc | 2,879 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 17:06:02 | 12.28 | 15,000 | 1,841.25 | O |
| 16:18:05 | 11.80 | 52,679 | 6,216.12 | O |
| 15:32:26 | 12.15 | 12,322 | 1,497.12 | O |
| 12:47:49 | 12.00 | 100,000 | 12,000.00 | O |
| 10:54:45 | 12.90 | 15,000 | 1,935.00 | O |
| Top Posts |
|---|
Posted at 04/12/2023 08:20 by C4x Discovery Daily Update C4x Discovery Holdings Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker C4XD. The last closing price for C4x Discovery was 13p.C4x Discovery currently has 252,227,097 shares in issue. The market capitalisation of C4x Discovery is £32,789,523. C4x Discovery has a price to earnings ratio (PE ratio) of -4.01. This morning C4XD shares opened at - |
Posted at 27/9/2023 06:19 by copandrobber So little stock trading! Small volumes move price down a lot. They need to do some IR.Nothing wrong with fundamentals, full of cash and good prospects. This one is a patience game! |
Posted at 01/8/2023 07:44 by 1aconic It probably needs to be viewed in context and with realistic expectations. It probably is a good deal for shareholders if it eliminates entirely (which is should) the spector of another dilutive fund raise. We're not in an ideal world currently and biotech funding isn't flavour of the month. Just calculate the dilution of future profits on ALL assets in the portfolio if they'd raised the same money at 15p (which in the current market is about what we could realistically expect). INDV-2000 may have been a case of "taking one for the team" and in context may have created more substantial shareholder value than it sacrifices if you acknowlege that other non-dilutive funding options weren't available.It provides funds to progress other programmes (notably Alpha4Beta7) further before partnering. If the deal on Alpha4Beta7 is better as a result, it may prove a masterstroke. We can look at Morphic's share price for reference and reflect on the fact that C4X's asset looks to be vastly superior. |
Posted at 13/6/2023 22:47 by alloa2003 I dont know if anyone has noticed but PatientSeek could be a game changer for C4XD, on top of the potential drug revenues further down the line. In the test they were able to tell, using a person's DNA, which Parkinsons treatment would work best for each patient. Personal medication - the Holy Grail - with potentially massive life and cost savings for the NHS, etc.We should be discussing this as well. |
Posted at 08/6/2023 12:12 by bloomberg2 ETX work closely with C4XD !!! Something cooking |
Posted at 26/4/2023 08:40 by copandrobber This is such a good buy at this price! If anyone ventures onto this board, have a look at their half year results and then enjoy buying a great company that is totally overlooked and undervalued! This will get taken out or taken private at a significantly higher price than it is today!! You heard it here first!! |
Posted at 19/1/2023 14:10 by davemac3 that RNS looks like an attempt to shore up the share price. We need some milestone payments from the partnered projects or I can see another fund raise in the not too distant future. |
Posted at 02/12/2022 13:41 by alloa2003 I have been in and out of this over the years and always kept a close eye on the company. You are correct, they are getting bundled in with the speculative pharma rubbish. The AZ deal has been in negotiations for ages and people are misisng the point, the $16m payment pre-clinical trials (with $2m up front) is AZ paying C4XD to do the work themselves, madness the market has missed this. This is C4XD's biggest pre-clinical trial payment to date.As far as funding, they had cash, then the £5m placing and now the $2m payment with more to follow. I think I read they have enought cash for at least 2 years. As soon as one drug goes to market this will become a cash cow. Many people are also missing the point with the payments. As well as stage payment due when a compound gets to market, C4XD will get royalties forever which is where the big bucks come in. So overlooked it is unreal. Just my view, DYOR |
Posted at 30/11/2022 18:27 by ivor hunch I am a firm believer in the potential of this company. Marketcap is £57 million but there is over $1 billion deals in the pipeline, and more to come. The only reason c4xd is not flying is the market's horror of any speculative share. This week c4xd announced a mega deal with AstraZeneca. A few years ago, pre-Covid, the news would have sent the shares soaring. Instead they rose 35% in the morning then continued to fall to below this summer's issue price of 25p. It's madness really, especially if the 3 deals proceed as planned - Indivior, Sanofi and AstraZeneca - all major players.Someone tell me what I'm missing please... |
Posted at 29/11/2022 08:00 by alloa2003 Been in and out of this one over the years and looking to get back in with a large chunk if other investments come through. The share price move is madness - this is still a big deal and there is at least one huge one still to come in the short term. The up front payment is substantial and lets not forget institutions approached the company about the recent fund raising at 25p. When one or more treatments hits the market, this will release huge milestone payments and - as some people seem to forget - a royalty forever. |
Posted at 25/8/2020 21:20 by the stigologist Perfectly normal for Deputy Chair of UK Vaccine Taskforce to speak to Bill GatesInterestingly Bill Gates is one of biggest investors in Schrodinger (SDGR) Mkt Cap $5bn Schrodinger is the nearest equivalent to C4XD IF C4XD share price doesn't go up soon I can see a US Company snapping them up for 100p+ The Indivior deal alone at $294m makes C4XD cheap at 100p (c.£130m Mkt Cap) Clive today told us the NRF2/IL17/a4B7 projects have similar potential |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
|
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions Support: +44 (0) 203 8794 460 | support@advfn.com |
| ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil |
| ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico |
| ADVFN France ADVFN US ADVFN Korea |
